Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: Immunogenicity of Als3p/Hyr1p dual antigen vaccine formulated with alum, CAF01, or BDX100 adjuvants. (A). Combination of Als3p/Hyr1p doses by checkerboard method. (B). Schematic of the experimental design for determining vaccine-induced immunogenicity is shown. The ICR CD-1 mice ( N = 5/group) vaccinated SC (Alum, CAF01) or IN (BDX100) with different vaccine formulations (Als3p and Hyr1p antigens ratio on the x-axis) on days 0 and 21. Two weeks after the final vaccination, serum antigen-specific IgG titers and T cells were evaluated using ELISA and FluroSpot assay, respectively. Comparison of (C). Anti-Als3p and (D). anti-Hyr1p IgG endpoint titers in alum, CAF01 or BDX100 adjuvant-antigen formulations. Anti-Als3p and anti-Hyr1p IgG endpoint titers in (E). alum, (F). CAF01, (G). BDX100 adjuvant-antigen formulations. (H). Heat map showing the mean frequency ( n = 5 mice/cell/formulation) of Als3p or Hyr1p-specific Th1, Th2, and Th17 cells (IFN- γ, IL-4 or IL17 producing cells) in mice vaccinated with alum, CAF01 or BDX100 vaccine formulations. Each row represents data from each vaccine formulation. (I). Bar graph showing Als3p or Hyr1p-specific Th1, Th2, and Th17 cells.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Flurospot, Comparison, Adjuvant, Formulation

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: Mechanism of VXV-01-mediated protection. Naïve mice or vaccinated mice ( n = 10 mice/group) were infected with C. albicans or C. auris . For vaccination, the VXV-01 or placebo (adjuvant only) was administered on days 0, 21, and 35 (for C. albicans infection) or days 0 and 21 (for C. auris infection). Mice were immunosuppressed with cyclophosphamide and cortisone acetate for C. auris infection. Naïve mice ( n = 10 mice/group) infected with (A). C. albicans or (C). C. auris received two intraperitoneal anti-sera injections at 2 and 168 h relative to infection. Vaccinated mice ( n = 10 mice/group) received anti-CD4 or isotype control antibodies to deplete the CD T cells. The mice were infected with (B). C. albicans or (D). C. auris . Mice survivals were compared by Mantel-Cox test, and p < 0.5 was considered statistically significant.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Infection, Adjuvant, Control

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: The durability of VXV-01 vaccine-induced immunity. The ICR (CD-1) mice were vaccinated sub-cutaneously with VXV-01 or placebo (adjuvant alone) on days: (A). 0, 21; or (B). 0, 21, 35. The serum anti-Als3p and anti-Hyr1p IgG endpoint titers and T cells were evaluated using ELISA and FluroSpot assay on days 14, 28, 90, 180, and 270 post-final vaccination. ( C ). Anti-Als3p, and ( D ). Hyr1p IgG endpoint titers and T-cell responses were compared between two and three vaccination schedules over the period of 270 days post-vaccination. Data presented as mean ± SE of N = 5 mice/group. ( E ). VXV-01 efficacy was tested after 15 weeks of final two doses vaccination regimen (day 0, 21) against C. auris infection in immunosuppressed mice ( N = 10 mice/group). Survival curves were compared by the Mantel-Cox test, and p < 0.5 was considered statistically significant.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Adjuvant, Enzyme-linked Immunosorbent Assay, Flurospot, Infection

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: Immunogenicity of Als3p/Hyr1p dual antigen vaccine formulated with alum, CAF01, or BDX100 adjuvants. (A). Combination of Als3p/Hyr1p doses by checkerboard method. (B). Schematic of the experimental design for determining vaccine-induced immunogenicity is shown. The ICR CD-1 mice ( N = 5/group) vaccinated SC (Alum, CAF01) or IN (BDX100) with different vaccine formulations (Als3p and Hyr1p antigens ratio on the x-axis) on days 0 and 21. Two weeks after the final vaccination, serum antigen-specific IgG titers and T cells were evaluated using ELISA and FluroSpot assay, respectively. Comparison of (C). Anti-Als3p and (D). anti-Hyr1p IgG endpoint titers in alum, CAF01 or BDX100 adjuvant-antigen formulations. Anti-Als3p and anti-Hyr1p IgG endpoint titers in (E). alum, (F). CAF01, (G). BDX100 adjuvant-antigen formulations. (H). Heat map showing the mean frequency ( n = 5 mice/cell/formulation) of Als3p or Hyr1p-specific Th1, Th2, and Th17 cells (IFN- γ, IL-4 or IL17 producing cells) in mice vaccinated with alum, CAF01 or BDX100 vaccine formulations. Each row represents data from each vaccine formulation. (I). Bar graph showing Als3p or Hyr1p-specific Th1, Th2, and Th17 cells.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Flurospot, Comparison, Adjuvant, Formulation

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: The durability of VXV-01 vaccine-induced immunity. The ICR (CD-1) mice were vaccinated sub-cutaneously with VXV-01 or placebo (adjuvant alone) on days: (A). 0, 21; or (B). 0, 21, 35. The serum anti-Als3p and anti-Hyr1p IgG endpoint titers and T cells were evaluated using ELISA and FluroSpot assay on days 14, 28, 90, 180, and 270 post-final vaccination. ( C ). Anti-Als3p, and ( D ). Hyr1p IgG endpoint titers and T-cell responses were compared between two and three vaccination schedules over the period of 270 days post-vaccination. Data presented as mean ± SE of N = 5 mice/group. ( E ). VXV-01 efficacy was tested after 15 weeks of final two doses vaccination regimen (day 0, 21) against C. auris infection in immunosuppressed mice ( N = 10 mice/group). Survival curves were compared by the Mantel-Cox test, and p < 0.5 was considered statistically significant.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Adjuvant, Enzyme-linked Immunosorbent Assay, Flurospot, Infection

Journal: Nature Communications

Article Title: Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

doi: 10.1038/s41467-026-68834-1

Figure Lengend Snippet: A Confirmation of CD8 + depletion by flow cytometry. Gating strategy: Supplementary Fig. . B – K MC38 tumor-bearing mice received 2 Gy 90 Y-, 177 Lu-, or 225 Ac-NM600 + ICI (days −3/0/3) + αCD8 (anti-CD8 on days −5/0/5), RPT + ICI, RPT alone, or αCD8 alone. Effects of CD8 + depletion on tumor growth ( B – H ) and overall survival ( I – K ) are shown. L Flow cytometry treatment scheme. MC38 tumor-bearing mice were randomized to receive either 2 Gy 90 Y-, 177 Lu-, or 225 Ac-NM600 + ICI (days −3/0/3), ICI alone, or untreated control (No Tx). M , N Tumors were harvested on days −3, 4, 8, or 11 and dissociated. The tumor immune infiltrate was analyzed by flow cytometry. Gating strategy: Supplementary Fig. . O Co-culture experiment scheme. Created https://BioRender.com/22ha1p4 . P , Q TNF and IFNγ expression were measured by intracellular flow cytometry staining and analysis of peripheral CD8 + effector memory cells (CD8 + CD44 + CD62L − ) harvested from naïve C57BL/6 mice or treated MC38 tumor-bearing mice following 24 h of co-culture with MC38 or no tumor cells. Gating strategy: Supplementary Fig. . A – H ; M , N ; P , Q Results of one experiment. I – K Results of two independent experiments. A N = 15: depleted; n = 7: IgG2b control. B – H N = 7: 90 Y-, 177 Lu-, 225 Ac-NM600 ± ICI; n = 5: 90 Y-, 177 Lu-, 225 Ac-NM600 + ICI + αCD8, αCD8. I – K N = 17: 90 Y-, 177 Lu-, 225 Ac-NM600 ± ICI; n = 10: αCD8; n = 5: 90 Y-, 177 Lu-, 225 Ac-NM600 + ICI + αCD8. M , N N = 5/treatment group and timepoint except n = 4: 90 Y-NM600 + ICI Day 4; 90 Y-, 177 Lu-, 225 Ac-NM600 + ICI Day 11. P , Q N = 5: naïve, 2 Gy 90 Y-NM600 + ICI; n = 6: ICI, 2 Gy 177 Lu-NM600 + ICI; n = 7: 2 Gy 225 Ac-NM600 + ICI. Unpaired two-tailed t-test was used to compare CD8 + frequency between groups. One-way ANOVA with Tukey’s HSD post hoc test was used to compare flow cytometry results between treatment groups for each marker and timepoint and TNF or IFNγ expression between treatment groups within each co-culture condition. Linear mixed models were used to compare tumor volumes over time between various treatment groups. Statistical testing of the pairwise contrasts was adjusted for multiple comparisons using Tukey’s method. Log-rank test was used to compare survival. Error bars are SEM. O Created in BioRender. Jin, W. (2026) https://BioRender.com/22ha1p4 .

Article Snippet: CD8 + T cell depletion was performed by injection of anti-murine CD8α (Rat IgG2b, κ; Clone 2.43; BioXCell, Cat # BE0061) or IgG2b control (Rat IgG2b, κ; Clone LTF-2; BioXCell, Cat # BE0090) by 300 μg intraperitoneal injection on days −5, 0, and 5.

Techniques: Flow Cytometry, Control, Co-Culture Assay, Expressing, Staining, Two Tailed Test, Marker

Journal: Nature Communications

Article Title: Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

doi: 10.1038/s41467-026-68834-1

Figure Lengend Snippet: MC38 tumor-bearing mice received IgG2b control on days −5/0/5 (IgG2b), or 0, 0.2 Gy (0.4625 kBq), 2 Gy (4.625 kBq), 8 Gy (18.5 kBq) 225 Ac-NM600 on day 1 ± ICI on days −3/0/3. A Body weights. B Complete blood counts on day 23. WBC white blood cells, LYM lymphocytes, PLT platelets, HGB hemoglobin, RBC red blood cells. C TNF and IFNγ on peripheral CD8 + effector memory cells (CD8 + CD44 + CD62L − ) from naïve or MC38 tumor-bearing mice receiving the indicated treatment and following 24 h of co-culture with MC38 or no tumor cells (from Fig. ). D – L MC38 tumor-bearing mice received 8 Gy 225 Ac-NM600 + ICI, 8 Gy 225 Ac-NM600, ICI, or were untreated (No Tx). D Experimental scheme. Created with BioRender.com. Tumor growth ( E ) and overall survival ( F ) are shown. G Complete response (CR) rates ( H ) and percent of CR mice and naïve controls rejecting rechallenge with MC38 cells are shown. I – K Flow cytometry of blood from CR (MC38, Ac + ICI) or naïve mice (MC38, naïve). L Flow cytometry of splenocytes from CR 225 Ac-NM600 + ICI mice that did not (Ac + ICI tumor) or did reject rechallenge (Ac + ICI no tumor), CR ICI mice (ICI), naïve C57BL/6 mice following IV injection of MC38 cells (MC38 IV), and completely naïve C57BL/6 mice (Naïve). Gating strategies: Supplementary Figs. – . A , B ; C ; E – L Results of one experiment. A N = 7: all groups. B N = 5: naïve, 2 Gy 90 Y-NM600 + ICI; n = 6: ICI, 2 Gy 177 Lu-NM600 + ICI; n = 7: 0.2, 2, 8 Gy 225 Ac-NM600 + ICI. C N = 5: naïve; n = 6: ICI; n = 7: 0.2, 2, 8 Gy 225 Ac-NM600 + ICI. E – G N = 5/treatment group. H N = 5: 225 Ac-NM600 + ICI, naïve; n = 3: ICI. I – K N = 4/treatment group. L N = 4: MC38 IV, Naïve; n = 3: ICI; n = 2: Ac + ICI tumor, Ac + ICI no tumor. One-way ANOVA with Tukey’s HSD post hoc test was used to compare TNF or IFNγ expression, blood counts, CR rates, rechallenge rejection rates, and spleen flow cytometry. Unpaired two-tailed t-test was used to compare blood flow cytometry. Tumor volumes were compared using linear mixed models adjusted for multiple comparisons using Tukey’s method. Log-rank test was used to compare survival. Error bars are SEM. D Created in BioRender. Berg, T. (2026) https://BioRender.com/llbyoho, .

Article Snippet: CD8 + T cell depletion was performed by injection of anti-murine CD8α (Rat IgG2b, κ; Clone 2.43; BioXCell, Cat # BE0061) or IgG2b control (Rat IgG2b, κ; Clone LTF-2; BioXCell, Cat # BE0090) by 300 μg intraperitoneal injection on days −5, 0, and 5.

Techniques: Control, Co-Culture Assay, Flow Cytometry, IV Injection, Expressing, Two Tailed Test

Journal: Nature Communications

Article Title: Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

doi: 10.1038/s41467-026-68834-1

Figure Lengend Snippet: Paired TCR sequencing analysis performed on samples from B78 tumor-bearing mice used for single cell RNA sequencing. A – H Data presented are from samples from experiment depicted in Fig. . A UMAP plots of T cells stratified by sample. B TCR clonotype expansion ranges. C UMAP plots of T cells stratified by T cell subtype. D Clonal expansion by treatment group and T cell subtype. E D50 score by treatment group and T cell subtype. F Relative abundance of clonal indices for each treatment group and T cell subtype. G UpSet plot showing shared clonotypes between T cell subtypes for the 225 Ac-NM600 + ICI sample. Red box demarcates CD8 + effector and memory subsets; red arrow demarcates # of shared clonotypes between CD8 + effector and memory subsets (=11). H UpSet plots showing shared clonotypes between T cell subtypes for the 90 Y-, 177 Lu-, EBRT + ICI, and ICI alone samples. For each plot, red arrow demarcates # of shared clonotypes between CD8+ effector and memory subsets (=7 for each sample). A – H Results of one experiment. 3 mice/treatment group pooled into one sample/treatment group for TCR sequencing analysis. Numbers of cells analyzed provided in Supplementary Table . Number of cells analyzed: 90 Y-NM600 + ICI, n = 408; 177 Lu-NM600 + ICI, n = 993; 225 Ac-NM600 + ICI, n = 854; EBRT + ICI, n = 285; ICI, n = 977.

Article Snippet: CD8 + T cell depletion was performed by injection of anti-murine CD8α (Rat IgG2b, κ; Clone 2.43; BioXCell, Cat # BE0061) or IgG2b control (Rat IgG2b, κ; Clone LTF-2; BioXCell, Cat # BE0090) by 300 μg intraperitoneal injection on days −5, 0, and 5.

Techniques: Sequencing, Single Cell, RNA Sequencing

Journal: Nature Communications

Article Title: Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

doi: 10.1038/s41467-026-68834-1

Figure Lengend Snippet: A – D Data presented are from samples from experiment depicted in Fig. . A Pathway enrichment results for CD8 + effector T cells. The bluer the pathway, the lower the adjusted P, and thus the more significantly the pathway is altered. Differential gene expression heat map for interferon γ ( B ) and interferon α ( C ) response genes for CD8 + effector T cells. The color of each box represents the log 2 (fold change) of gene expression of 225 Ac-, 177 Lu-, 90 Y-NM600, or EBRT + ICI compared to ICI alone. D Incidence matrix of differential gene expression between treatment groups of the following: comparing cells where the shared clonotypes between effector and memory CD8 + T cells are between 7 and 11 (as shown in Fig. ), and they are amplified. Red arrow marks interferon-inducible gene, Ifi27l2a , which is upregulated in these shared clonotype CD8 + cell populations treated with 225 Ac-NM600 + ICI over each treatment group. A – D Results of one experiment. 3 mice/treatment group pooled into one sample/treatment group for single cell RNA sequencing TCR sequencing analysis. Benjamini–Hochberg method was used to correct for multiple comparison. Numbers of cells analyzed provided in Supplementary Table A – C 90 Y-NM600 + ICI, n = 6067; 177 Lu-NM600 + ICI, n = 9808; 225 Ac-NM600 + ICI, n = 6503; EBRT + ICI, n = 7045; ICI, n = 11,249 and Supplementary Table D 90 Y-NM600 + ICI, n = 123; 177 Lu-NM600 + ICI, n = 151; 225 Ac-NM600 + ICI, n = 45; EBRT + ICI, n = 36; ICI, n = 100.

Article Snippet: CD8 + T cell depletion was performed by injection of anti-murine CD8α (Rat IgG2b, κ; Clone 2.43; BioXCell, Cat # BE0061) or IgG2b control (Rat IgG2b, κ; Clone LTF-2; BioXCell, Cat # BE0090) by 300 μg intraperitoneal injection on days −5, 0, and 5.

Techniques: Gene Expression, Amplification, Single Cell, RNA Sequencing, Sequencing, Comparison

Journal: Nature Communications

Article Title: Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

doi: 10.1038/s41467-024-44932-w

Figure Lengend Snippet: a Flow cytometry analysis of CT2A CRISPR control, Atrx KO-A or KO-B tumor-bearing hemispheres harvested 14 days post-intracranial implant showing percent live cell density of CD3 + , CD4+ and CD8 + T-cells and macrophages (CD45 + , CD3/19neg, NK1.1neg, CD11bhi, CD45hi). Gating strategy is provided in Supplementary Fig. . n = 10 for CRISPR control – CD3 + , CD4 + , CD8+ markers; n = 9 for CRISPR control - macrophage markers; n = 7 for Atrx KO-A - all markers; n = 5 for Atrx KO-B – all markers; n = 9 for normal brain - CD3 + , CD4 + , CD8+ markers; n = 8 for normal brain – macrophage markers. Data are presented as mean ± SEM. Asterisks denote significant one-way ANOVA with Dunnett’s post-hoc test comparing CRISPR control with Atrx KO tumor-bearing hemispheres (* p < 0.05, ** p < 0.01). CD3 + : Control vs Atrx KO-A – p = 0.0296; CD4 + : Control vs Atrx KO-A – p = 0.0117; Macrophages: Control vs Atrx KO-A – p = 0.0167, Control vs Atrx KO-B – p = 0.0086. b Representative IHC images for CD45 (A, B, C) and F4/80 (D, E, F) expression (brown) in CT2A CRISPR Control ( Atrx WT ) (A, D), Atrx KO-A (B, E) and KO-B (C, F) tumors, with hematoxylin counter-staining (blue). Scale bar: 50μm. Number of brains subjected to IHC per group: CRISPR Control – n = 3; Atrx KO-A – n = 2; Atrx KO-B – n = 3. c Representative IHC images for CD45 (A, B) and CD3 (C, D) expression (brown) in RCAS/ Ntv-a control (A, C) and Atrx -KO (B, D), with hematoxylin counter-staining. Scale bar: 50μm. Number of brains subjected to IHC per group: RCAS/ Ntv-a control – n = 6; Atrx KO – n = 4. d , e Kaplan–Meir survival curves for C57BL/6 mice bearing intracranial CT2A CRISPR ctrl (Control) or Atrx KO-B tumors treated with 250 μg of isotype control IgG, anti-CD4 antibody ( d ) or anti-CD8 antibody ( e ) as per schema in Supplementary Fig. . N Number of mice per group; MS median survival in days. P -values represent group comparisons calculated using log-rank test. Source data are provided as a Source Data file.

Article Snippet: For CD4+ and CD8 + T-cell depletion experiments, C57BL/6 mice ( n = 10 mice per group) received 250 μg per dose of rat IgG2B isotype control (BioXcell, Cat. no. BE0090), anti-mouse CD4 antibody (BioXcell, Cat. no. BE00003) or anti-mouse CD8 antibody (BioXcell, Cat no. BE0061) intraperitoneally 4 days prior to implant.

Techniques: Flow Cytometry, CRISPR, Control, Expressing, Staining

Journal: bioRxiv

Article Title: A class act: HDAC1- Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells

doi: 10.64898/2026.03.23.713743

Figure Lengend Snippet: (A) UMAP visualization of major cell clusters identified from single cell RNA sequencing (scRNA-seq) of NT2.5-LM breast-to-lung metastatic tumors after 3 weeks of treatment with: vehicle (V), Entinostat (E), anti-CTLA-4 + anti-PD-1 immune checkpoint inhibitors (PC), and Entinostat + anti-CTLA-4 + anti-PD-1 combination (EPC). Subclusters of MDSCs identified: G-MDSCs and M-MDSCs. (B) Iterative logistic regression analyses conducted on the major MDSC cluster comparing the Vehicle (V) and Entinostat + ICIs combination treatment (EPC). (C) Expression of Malat1 / MALAT1 in G- and M-MDSCs isolated from lung metastases of NT2.5-LM mice treated with vehicle vs. Entinostat for 3 weeks (left, n=2 from 5 pooled mice per treatment group), J774M murine MDSC-like cell line treated with Entinostat for 24 hours (middle, n=3), and human PBMC-derived MDSCs (hMDSCs) treated with Entinostat for 24 hours (right, n=3). (D) Median Fluorescence Intensity expression of Malat1 in CD45 + CD11b + MHC-II - F4/80 - Ly6G - Ly6C hi cells from lung metastases in 4T1 mice, treated with vehicle (V), Entinostat (E), and Entinostat + ICIs (EPC) for 3 weeks. (E) Expression of Malat1 in J774M cell line treated with various concentrations of various HDAC inhibitors, with corresponding targeted class and specific HDACs. One-way ANOVA for (C, E: all statistically significant with p<0.05, unless indicated as non-significant (ns)), Kruskal-Wallis test with Dunn’s correction for (D). * p<0.05, *** p< 0.001, **** p<0.0001. ENT = Entinostat; PAN = Panobinostat; BEL = Belinostat; VOR = Vorinostat; TSA = Trichostatin A; DOM = Domatinostat; CHL = Chlopynostat; PYR = Pyroxamide; SCA = Santacruzamate A; RGF = RGFP966; TMP = TMP269; SIS = SIS17.

Article Snippet: Immune checkpoint inhibitors (ICIs) used in this study: anti-CTLA-4 (BioXCell cat. #BE0131) and anti-PD-1 (BioXCell cat. #BE0146).

Techniques: Single Cell, RNA Sequencing, Expressing, Isolation, Derivative Assay, Fluorescence